secwatch.observer — SEC 8-K summary
======================================

Issuer:     Semnur Pharmaceuticals, Inc. (SMNR)
CIK:        0001913577
Form:       8-K
Filed at:   2025-04-16T23:59:59+00:00
Accession:  0001213900-25-032299
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali Capital shareholders approve extension to Dec 2025; ~708K shares redeemed for ~$8.6M
--------------------------------------------------------------------------------

- Shareholders voted to extend business combination deadline to December 11, 2025, via up to 8 monthly extensions.
- Holders of ~708,098 Class A shares redeemed for ~$8.6M (~$12.17/share); only 43,739 Class A shares remain outstanding.
- Company deposited $874.78 into trust for first extension to May 11, 2025, funded by Scilex convertible note (up to $180K).
- Scilex note bears no interest, convertible at $10/share; remaining $58,670.30 available for future extensions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1913577/000121390025032299/0001213900-25-032299-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1913577/000121390025032299/ea0238488-8k_denali.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-032299

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer